Should We Routinely Screen for Warfarin Gene Polymorphism in Patients with Coumadin Overdose?

dc.contributor.authorGul, Enes Elvin
dc.contributor.authorErdogan, Halil Ibrahim
dc.contributor.authorYazici, Mehmet
dc.date.accessioned2020-03-26T19:26:22Z
dc.date.available2020-03-26T19:26:22Z
dc.date.issued2016
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractGenetic polymorphisms can affect an individual's response to the pharmacological agents. Warfarin has a narrow therapeutic range and dose arrangement may vary from individual to individual. An insufficient dose may fail to prevent thromboembolism and overdose may increase the risk of bleeding. Increasing evidence suggests that genetic variation of CYP2C9 and VKORC1 greatly influences effective warfarin dosing (1). In the present case report, frequently occurring warfarin toxicity was caused by a genetic mutation in the patient with mitral valve replacement.en_US
dc.identifier.doi10.5152/eajem.2016.83702en_US
dc.identifier.endpage201en_US
dc.identifier.issn2149-5807en_US
dc.identifier.issn2149-6048en_US
dc.identifier.issue4en_US
dc.identifier.pmid#YOKen_US
dc.identifier.startpage199en_US
dc.identifier.urihttps://dx.doi.org/10.5152/eajem.2016.83702
dc.identifier.urihttps://hdl.handle.net/20.500.12395/33996
dc.identifier.volume15en_US
dc.identifier.wosWOS:000391005500010en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherAVESen_US
dc.relation.ispartofEURASIAN JOURNAL OF EMERGENCY MEDICINEen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectwarfarinen_US
dc.subjectgeneticen_US
dc.subjectCYP2C9en_US
dc.subjectVKORC1en_US
dc.titleShould We Routinely Screen for Warfarin Gene Polymorphism in Patients with Coumadin Overdose?en_US
dc.typeArticleen_US

Dosyalar